Wednesday, 2nd November Clinical Oncology Society of Australia Annual Scientific Meeting 2022

This symposium will provide an overview of the COSA Position Statement on Cancer-Related Malnutrition and Sarcopenia. The session will showcase the latest research on identification, assessment and treatment of malnutrition and sarcopenia highlighting practical tips to overcome common barriers, leverage enablers and multidisciplinary care to optimise management of these conditions and cancer outcomes overall.

Speakers:

• Associate Professor Nicole Kiss, Deakin University
• Professor Judy Bauer, Monash University
• Jenelle Loeliger, Peter MacCallum Cancer Centre
• Belinda Steer, Peter MacCallum Cancer Centre
• Multidisciplinary Discussion Panel TBC
• Dietitian, Exercise Physiologist, Nurse, Oncologist

This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition Group

Welcome by COSA President
Welcome to Country

• Inequities in cancer outcomes for Aboriginal and Torres Strait Islander peoples with cancer - Lisa Whop
• Culture clash: racial disparities in cancer care and outcomes - Ben Smith
• Out with cancer: LGBTQI+ cancer survivorship and care - Jane Ussher

• omGFR! - update on renal dosing anticancer drugs in frail patients - Geeta Sandhu
• Medicine sequencing matters: drug sequencing for targeted therapies for NSCLC - Malinda Itchins
• Telephone versus videoconference pharmacist consults for medication history taking: which modality is more successful across the distance? - Marissa Ryan
• Oral targeted therapies in non-small cell cancer – managing toxicities - Marliese Alexander

Followed by Panel discussion

• Managing fear of recurrence and progression: an update - Phyllis N Butow
• Fear of cancer recurrence among Aboriginal and Torres Strait Islander women diagnosed with breast cancer - Gail Garvey
• Fear of Recurrence: the role of the clinician in addressing the elephant in the room - Jia (Jenny) Liu
• When cancer HAS recurred: adapting FCR interventions in metastatic populations to target fear of cancer progression - Lisa Beatty

Followed by Panel discussion

• Lung cancer comprehensive genomic profiling - Nic Waddell
• Delivering precision medicine for non-small cell lung cancer: the ASPiRATION trial - Ben Solomon
• Tissue-resident memory T cells accelerate tumour evolution in lung cancer - Marie-Liesse Asselin-Labat
• Non-invasive extracellular vesicle biomarkers for the diagnosis of early stage NSCLC - Andreas Moeller

• Exploring factors influencing COVID-19 vaccine hesitancy among people with cancer: a qualitative analysis.   - Bryan Chan
• Emotional transformations during Victoria’s Cancer Council 131120 information and support service calls detected using Artificial Intelligence - Jessica Bucholc
• The Australian Rare Cancer Portal: outcomes from the implementation of a national rare cancer platform for referrals and research - Chloe L Georgiou
• SMARTscreen: using a novel SMS with narrative communication to increase uptake of the National Bowel Cancer Screening Program - Jennifer G McIntosh
• Supporting best practice telehealth in cancer care: findings from a national study of telehealth use by cancer services and consumers during the COVID-19 pandemic - Melissa Austen
• Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer - Yufan Wang

• "Living with NETs"  - online patient education program - Meredith Cummins
• The cancer exercise toolkit: giving exercise professionals online tools to bridge the evidence-practice gap - Amy Dennett
• Evaluating and defining consumer-led research in a large melanoma collaborative cohort. - Sonia L Mailer
• Improving capacity for equitable end-of-life communication for adolescents and young adults with cancer: what training do health-professionals need to facilitate best-practice? - Ursula M Sansom-Daly
• Development and acceptability testing of a patient decision-aid for cancer patients with anxiety and depression to guide psycho-oncology treatment decisions - Joanne Shaw

• Frailty through the lens of geriatric oncology - Wee-Kheng Soo
• Its not just about cancer - Robyn Berry
• Patient derived goals - James A Fletcher
• Does my patient have frailty, malnutrition, sarcopenia or cachexia? - Vickie Baracos

Followed by Panel discussion

• Phase III Study of Adjuvant Encorafenib Plus Binimetinib Versus Placebo in Fully Resected Stage IIB/C BRAF^V600-Mutated Melanoma: COLUMBUS-AD Study Design - Victoria Atkinson
• Colorectal cancer stem cells and hypoxia - Reem ALHulais
• Facilitators for participation in mail-out bowel cancer screening programs - Laura E Anderson
• Physical, psychological, and quality of life outcomes in adults post allogeneic stem cell transplantation: A prospective cohort study. - Dominique Shreeve
• VCR Data Explorer – A public-facing user-friendly application to gain understanding on Victorian cancer incidence, mortality, survival and prevalence - Luc te Marvelde
• Pembrolizumab plus chemotherapy in persistent, recurrent, or metastatic cervical cancer: a KEYNOTE-826 subgroup analysis - Sally Baron-Hay
• Neoadjuvant pembrolizumab+chemotherapy vs placebo+chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: event-free survival sensitivity and subgroup analyses from KEYNOTE-522 - Sally Baron-Hay
• The prognostic significance of nutritional status in oesophageal and gastric adenocarcinoma. - Tamara Bosward
• Impacts and outcomes of COVID-19 infection in medical oncology patients in a Western Australian tertiary centre - Sowmya Cheruvu
• CELEBRATE: A Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) - Julia R Dixon-Douglas
• Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving Lenvatinib + Pembrolizumab (CLEAR Study) - Basant Ebaid
• Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study - Basant Ebaid
• Safety and efficacy of Sitravatinib + Tislelizumab in patients with PD-L1+, locally advanced/metastatic, nonsquamous NSCLC - Paul Smart
• Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC - Paul Smart
• Pharmacogenetic testing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1) based chemotherapies in routine clinical care: perspectives of medical oncologists and oncology pharmacists - Sarah Glewis
• A single centre review of contemporary systemic therapy in in-transit melanoma (ITM) - Amy Griffin
• LEAP-009: Phase 2 study of Lenvatinib with or without Pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 Inhibition) - Elani Bowers
• Efficacy and tolerability of docetaxel chemotherapy in “real-world” patients with metastatic hormone-sensitive prostate cancer (mHSPC) - May Tun Hla Maw
• Immunotherapy Efficacy and Concomitant Antibiotic Use in Advanced Cancers: Retrospective Analysis in a Regional Centre - Saw Htut
• Polypharmacy and prescription practices in the older oncology population at The Kinghorn Cancer Centre: a single site, retrospective audit.      - Joshua Hurwitz
• Prevalence of fatigue in patients with haematological malignancy: a systematic review. - Tegan Ilsley
• Implementation of an immunotherapy toxicity management clinic - Haakan A Jakobsson
• CDK4/6 Inhibitors (CKD4/6i) in advanced Hormone-Receptor-Positive (HR+) HER2-Negative (HER2-) breast cancer: prescribing practices and outcomes in a real-world, Australian cohort - Anadil Javaid
• Survival of patients with solid-organ malignancies referred to Nepean Hospital Rehabilitation services between 2018-2020 - Vikram Joshi
• Effective selection of patients with solid-organ malignancies for in-patient rehabilitation: analysis of cancer patients referred to Nepean Rehabilitation services between 2018-2020 - Vikram Joshi
• H2-antagonists for prevention of taxane infusion reactions: are these required? - Kimberley-Ann Kerr
• Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial - Ashish Banerjee
• Pembrolizumab+Chemotherapy vs Placebo+Chemotherapy by PD-L1 combined positive score 1-9, 10-19, and ≥20 for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer: KEYNOTE-355 subgroup analysis - Julia Douglas
• Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study  - Niamh Mangan
• Should I take aspirin? (SITA): An RCT of a decision aid to support informed choices about taking aspirin to prevent cancer and other chronic disease: trial results - Jennifer McIntosh
• Haematological and nutritional prognostic markers for patients receiving CROSS - Nicholas McNamee
• Incidence of NTRK fusions in non-small cell lung cancer - Jared Mathai
• Checkpoint inhibitor immunotherapy-induced radiation recall pneumonitis: a case series - Andrew O Parsonson
• Beyond the median: estimating survival times for patients starting endocrine therapy for estrogen receptor positive metastatic breast cancer - Andrew O Parsonson
• Patterns of first site of recurrence in patients treated with Merkel cell carcinoma: The Westmead hospital experience, Sydney.   - ishaan Pillay
• The effect of exercise on cancer-related pain: a systematic review with meta-analysis - Melanie L Plinsinga
• Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100 - David W. Pook
• Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): results from patients with ≥12 months of treatment in JAVELIN Bladder 100 - David W. Pook
• Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy - David W. Pook
• Chemotherapy response following immunotherapy in metastatic head and neck cancer; a single-centre experience - Anthony Rodrigues
• The uptake of germline and somatic BRCA mutation testing in women with high grade serous ovarian cancer in the public hospital system in South Australia  - Andry Santoso
• Patterns of care post progression for NSCLC patients treated with definitive chemoradiation and durvalumab - Adel Shahnam
• Acceptability and feasibility of personalised, systematic melanoma risk assessment from the perspective of patients and clinic staff: a qualitative study - Amelia K Smit
• First do no harm: practical recommendations for harms reporting in Exercise Oncology - Rosa R Spence
• Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol - Rebecca Symons
• Atezolizumab and bevacizumab for advanced hepatocellular carcinoma: a single centre real world experience - Pei Ying Tan
• Adjuvant therapy in resected melanoma: Experience from Royal Brisbane and Women’s Hospital - Cassie L Turner
• Solving unknown primary cancer - earlier diagnosis (SUPER-ED): a stepped wedge cluster randomised controlled trial implementing a model of care to support earlier diagnosis. - Anna Ugalde
• Real world outcomes of Ipilimumab and Nivolumab in patients with advanced renal cell carcinoma - Sarah Williams
• AI-assisted clinical trial recruitment using an open-source Natural Language Processing workflow - Anne Woollett
• Patient experiences of prolonged living with cancer during early phase trial treatment - Oksana Zdanska
• Development of evidence-based key principles and best practice approaches to co-design with First Nations peoples applicable to the cancer context in Australia - Kate Anderson
• Increasing cervical screening participation for people living with intellectual disability: ScreenEQUAL – an innovative disability-inclusive study protocol to support equity - Deborah Bateson
• Screening for unmet needs of caregivers of people with brain cancer: development of a brief screening measure for use in clinical practice - Rachel Campbell
• Working in partnership to reduce cancer risk for LGBTQ+ people - Scott Walsberger
• eviQ and eviQ education opportunities to improve cancer outcomes for LGBTIQ+ communities - Scott Walsberger
• Cancer risk behaviours among LGBTQ+ people in NSW - Scott Walsberger
• The utility of molecular tumour profiling for patients with advanced cancer in a regional Australian setting - Natalie Chilko
• A call to action: improve cancer outcomes through increased research funding awarded for Aboriginal and Torres Strait Islander and culturally diverse communities   - Tilini Gunatillake
• “It’s not me, it’s you”: Taking a systems approach to health equity - Vijaya Joshi
• Breast cancer: a handbook for Aboriginal and Torres Strait Islander Health Workers and Health Practitioners - Kerri Lucas
• Our mob and cancer: co-designing a national website for Aboriginal and Torres Strait Islander people affected by cancer and their health professionals - Kerri Lucas
• A rare cancer diagnosis highlighting ongoing health inequity for Aboriginal people and Australian’s living rurally - Sally Magoffin
• Pilot evaluation of the Lung Cancer Optimal Care Pathway for Aboriginal people in NSW - Brooke Stapleton
• Guiding transformative change to address inequity across the pancreatic cancer care continuum - Daniel Chaji
• Telehealth maintains access to early phase clinical trials during the Covid-19 pandemic - Jyoti Parmar
• Patient satisfaction with new models of clinical trial participation: a cross-sectional study at a rural cancer centre - Andrew O Parsonson
• Patterns of treatment and outcomes for patients with glioblastoma: a population-based study in Queensland - Suzanne Poulgrain
• Is health-related quality of life in rural cancer survivors better or worse than in urban survivors? A systematic review. - Eli Ristevski
• Recognising gender identity: promoting inclusive practice within Cancer Council SA’s 13 11 20 service - Amanda Robertson
• One participant’s narrative in a grounded theory study: cancer treatment for muscle invasive bladder cancer, disadvantages experienced living in rural Australia - Carli Shaw
• Establishing a national cancer care policy – Cancer Council   - Megan Varlow
• Tumour characteristics and outcomes of gastric and oesophageal cancer patients treated with curative intent in culturally and linguistically diverse (CALD) patients in South Western Sydney. - Robert Yoon
• Factors that influence cancer clinical trials participation in Australia: a Scoping Review - Kyung Ha (Kathy) You
• Evaluating automated data extraction for lung cancer pathology reports in NSW Cancer Registry - Hanyu Chen
• Real-world outcomes for patients with pleural mesothelioma: a multisite retrospective cohort study. - Kar Ven Cavan KVCC Chow
• Exploring lung cancer patient awareness, attitudes and practices of food-drug interactions with their targeted oral anticancer medications - Sonia Cuan
• Changing landscape of lung cancer survival in a regional Australian centre. - Ortis Estacio
• Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Analysis of all patients from VISION Cohorts A and C - Malinda Itchins
• Understanding the drivers for poor outcomes in lung cancer patients in a Victorian regional centre - Bridget Josephs
• Examining the unmet needs of older patients with lung cancer patients: a systematic review. - Nicole Knox
• Treatment patterns and long-term survival outcomes for patients with stage III non=small cell lung cancer - a retrospective study - Seema Dr Kumari
• Real-world comparative data on addition of Atezolizumab to platinum-doublet chemotherapy in extensive stage small cell lung cancer - a single South Australian institution experience - Yao J Ly
• Investigating symptoms of lung cancer: a guide for all health professionals - Vivienne Milch
• Impact of age on adverse event outcomes in advanced NSCLC treated with first-line anti-PD-(L)1 +/- chemotherapy - Alice Morris
• Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients: A case series - Geoffrey Peters
• Prognostic Nutritional Index (PNI) predicts progression free survival in patients with unresectable stage III non-small cell lung cancer treated with consolidation durvalumab - Adel Shahnam
• Role of hybrid FDG PET/contrast CT parameters at early restaging for subsequent response to immunotherapy in advanced NSCLC - Dalveer Singh
• COVID-19 impacts on lung cancer diagnosis, management and timeliness in Victoria, Australia - Luc te Marvelde
• The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC) - Cassie L Turner
• Investigating the incidence Febrile Neutropenia in Small Cell Lung Cancer (SCLC): Does adding ‘G’ make it ‘all G’? - Michael Whordley
• Hemophagocytic lymphohistiocytosis associated with targeted therapy using Dabrafenib and Trametinib - Taha Dr Al-Mufti
• Equitable cancer care for women with ovarian cancer – what does that look like? - Helen Gooden
• A survey of patient satisfaction with pharmacist education with medication profiles for cancer supportive medications - Kimberly-Ann KK Kerr
• Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: A systematic review - Kelly D'cunha
• Incidence and management of severe immune-related adverse events in a regional Australian setting. - Amy Davies
• Cardiovascular hospitalisations in Queensland Lung Cancer patients diagnosed (2013-15) - Abbey Diaz
• Variations in ethno-linguistic disparities as risk factor for prostate cancer and its aggressiveness in South Africa - Kazzem Gheybi
• RD-Stage at Diagnosis for pancreatic and endometrial cancer: validation process of the developed business rules - Kris Ivanova
• Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration - Natansh D Modi
• The health outcomes in people with cancer and comorbidities: the Australian National Health Survey analysis   - Huah Shin Ng
• Impact of COVID-19 on cancer diagnosis notifications in the Barwon Southwest region of Victoria - Graham Pitson
• Oncology Social Determinants of Health - Linh Van
• Establishing a shared care service (GPCanShare) for surveillance cancer patients. - Jeremy JC Chow
• Cancer care in the outback - Zoe M. R. Kirkman
• Development and consensus of ‘CIPN-Path’: a clinical pathway for the assessment and management of chemotherapy-induced Peripheral Neuropathy - David Mizrahi
• Advance care planning in cancer services: the evidence, national collaboration and sustainable resource development  - Helena Rodi
• An evaluation on the pharmacy and nursing impact of switching doxorubicin syringes to infusion bags in an Australian metropolitan cancer specialty hospital - Whiter Tang
• Informed financial consent processes in cancer services: implementation recommendations from early adopters in Australia  - Kate Whittaker
• Which is more effective, intravenous haloperidol or chlorpromazine, to improve agitation and communication in agitated terminal delirium? - Megumi Uchida
• Phase 3, randomized, double-blind, placebo-controlled study of Pembrolizumab+Chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49 - Dhanusha Sabanathan

• Patient power: empowering patients one conversation at a time - M LE MESURIER
• The value of peer support - Leonie Young
• The invisible backbone of cancer care – Improving support and management of family carers through communication - Phyllis Butow
• Yarning to inform a culturally-responsive Radiotherapy Talking Book for Aboriginal and Torres Strait Islander people undergoing radiotherapy - Bena Brown
• Old, aged, or over the hill: the language of ageism in cancer care - Michael S Krasovitsky

• Lung-sparing resections by advanced minimally invasive robotic surgery - Christopher Cao
• Genomics and the multidisciplinary team: hitting new targets - Malinda Itchins
• Oligometastases:  the role of radiation therapy in hitting metastatic targets   - Dasantha Jayamanne
• The role of the Nurse Practitioner in lung cancer - Rebecca Kimberley

• Planning for end-of-life decisions - Ben White
• Timely access to palliative care in lung cancer through an equity lens - Kathy Eagar
• Palliative care in lung cancer: an update - Jaclyn Yoong
• The patient voice - Michel Itel

• Patterns of care for men with localised prostate cancer: results from the Prostate Cancer Outcomes Registry- Australia and New Zealand database - Karen Chiam
• E-Path Plus: using artificial intelligence to build cancer registry capability - Fiona Kennett
• Appendiceal neuroendocrine tumours in individuals under the age of 50 years: a population-based study from Queensland, Australia - William Moorhead
• Cutaneous melanoma, prostate specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study. - Visalini Nair-Shalliker
• How would the choice of health-related quality of life measure affect the cost-effectiveness of oncology interventions? - Haitham Tuffaha
• Understanding the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis - Larissa Vaz Goncalves

• Prehabilitation before gastrointestinal cancer surgery (PREHAB-GI): an implementation study. - Kristy-Lee Raso
• RECALL:Reliability of Estimates of Clinicians’Lung cancer caseLoad – a comparison of clinician estimates of key study eligibility criteria with data from the INHALE registry - Emmy Sneath
• Developing resources to support Australian families to care for someone at the end of their life: A literature review, scoping study and qualitative study - Kristina Thomas
• Angiotensin receptor 1 blockade blocks cancer-induced memory impairment in a mouse model of breast cancer. - Adam K Walker
• How much? The real cost of weight-based dosing of G-CSF for rural patients - Kate Wright

Welcome - Malinda Itchins
1^st Line treatment of mNSCLC with ICI in 2022: what does the longer-term data tell us? - Malinda Itchins
Survivorship of patients with lung cancer - Mary Duffy
Sharing perspectives on managing patients who have completed their PBS-funded treatment - All 
Followed by Q&A